s
Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel
21-08-2024, 13:33
ANNAPOLIS, Md., Aug. 20, 2024 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that it has received a notice of claims allowance from the U.S. Patent and Trademark Office (USPTO) covering compositions and methods of use for the drug formulation of Zabalafin Hydrogel (AB-101a) for atopic dermatitis. Once issued, the […] L'articolo Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel proviene da La Ragione.
CONTINUA A LEGGERE
13
0
0